Skip To Main Content
Gabriel Costa on Muck Rack

Gabriel Costa

As seen in: Amazon Web Services, G1 Globo, Medium, Valor Econômico, Estadão, Nature, Wiley Online Library, Zero Hora (Newspaper), Frontiers, Frontiers in Immunology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gabriel

Contact Gabriel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cannabinoid neuropharmacology across the lifespan: how aging recalibrates risk and benefit

|
By Gabriel Costa, Joao P. De Aquino
| Nature Verified
Adults aged 65 and older are the fastest-growing age cohort among people who use cannabis in the United States. Past-year cannabis use among older adults has risen almost 20-fold over two decades, and approximately one in three who use cannabis meet criteria for cannabis use disorder (CUD) [1]. Older adults commonly use cannabis to manage pain, sleep disturbance, and anxiety [1].
Open in Who Shared Issue with article?

Extend Amazon CloudWatch Beyond Native Connectors with Cribl Stream

|
By Kishore Vinjam, Gabriel Costa
| Amazon Web Services
Teams running hybrid or multi-cloud estates collect telemetry from proprietary appliances, on-premises Application Performance Monitoring (APM) tools, home-grown agents, and Apache Kafka streams that all must be parsed, normalized, and routed before it’s useful. Amazon CloudWatch lets you collect logs from 60+ AWS services, 20+ third-party tools, and your own applications using CloudWatch pipelines, HTTP endpoints, and agents.
Open in Who Shared Issue with article?

An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol

|
By Gabriel Costa, Mehmet Sofuoglu, Peggy Compton, Mohini Ranganathan, Brian Pittman, Joao P. De Aquino
| Nature Verified
Abstract Even during opioid agonist treatment (OAT) for opioid use disorder (OUD), chronic pain remains common and unrelieved, as opioids impair endogenous pain modulation. Cannabidiol (CBD) may represent a non-opioid adjunct, but its effects among persons with co-occurring OUD and chronic pain receiving OAT are unknown.
Open in Who Shared Issue with article?
See all 207 licensed articles (210 Total)